South Korea's Health Ministry Unveils Provisions For November's Anti-rebate Law
SEOUL - South Korea's Ministry of Health and Welfare outlined detailed provisions to implement a new "anti-rebate law," which will enable courts to punish both contributors and receivers of rebates. Passed overwhelmingly by South Korea's National Assembly on April 28, the law goes into effect Nov. 28, and will be enforced by the ministry.Under the new regulations, pharmas will be able to offer "sample" drugs as long as they are offered the "minimum packing unit," said the ministry, adding that they will also be able to offer minimal amounts of drugs and research fees to those conducting clinical trials
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.
The big pharma forecast a $400m expense this year related to tariffs, but those estimates only reflect medtech tariffs already announced, not potential pharma tariffs.
Sanofi’s OX40L candidate missed a Phase II primary endpoint, but the company believes it can still work in a sub-group of ‘heterogeneous inflammatory asthma’ patients.